{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:14:06Z","timestamp":1791220446051,"version":"4.1.0"},"reference-count":45,"publisher":"Siapec Servizi Srl","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-1565","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:31:08Z","timestamp":1775737868000},"page":"559-570","source":"Crossref","is-referenced-by-count":1,"title":["Standardizing the pathologic assessment of HER2-(ultra)low breast cancer: insights from a national Italian project"],"prefix":"10.32074","volume":"117","author":[{"given":"Bruna","family":"Cerbelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GIPaM working group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Marletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelina","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Costarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Errigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Foschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro G","family":"Mastropasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Orvieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pietribiasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Ragazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Santinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Zanconati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Scatena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"10.32074\/1591-951X-1565_ref1","doi-asserted-by":"crossref","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 2023;41:3867\u20133872. doi:10.1200\/JCO.22.02864.","DOI":"10.1200\/JCO.22.02864"},{"key":"10.32074\/1591-951X-1565_ref2","doi-asserted-by":"crossref","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N. Engl. J. Med. 2022;387:9\u201320. doi:10.1056\/NEJMoa2203690.","DOI":"10.1056\/NEJMc2210368"},{"key":"10.32074\/1591-951X-1565_ref3","doi-asserted-by":"crossref","unstructured":"Venetis K, Crimini E, Sajjadi E, et al. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Front. Mol. Biosci. 2022;9:834651. doi:10.3389\/fmolb.2022.834651.","DOI":"10.3389\/fmolb.2022.834651"},{"key":"10.32074\/1591-951X-1565_ref4","unstructured":"College of American Pathologists. Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast.; 2025."},{"key":"10.32074\/1591-951X-1565_ref5","doi-asserted-by":"crossref","unstructured":"Ivanova M, Porta FM, D\u2019Ercole M, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 2024;484:3\u201314. doi:10.1007\/s00428-023-03656-w.","DOI":"10.1007\/s00428-023-03656-w"},{"key":"10.32074\/1591-951X-1565_ref6","doi-asserted-by":"crossref","unstructured":"Zhong J, Gao B, Wang Q, et al. Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization. Diagn. Pathol. 2025;20:4. doi:10.1186\/s13000-024-01594-y.","DOI":"10.1186\/s13000-024-01594-y"},{"key":"10.32074\/1591-951X-1565_ref7","doi-asserted-by":"crossref","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 2021;7:1. doi:10.1038\/s41523-020-00208-2.","DOI":"10.1038\/s41523-020-00208-2"},{"key":"10.32074\/1591-951X-1565_ref8","doi-asserted-by":"crossref","unstructured":"Sapino A, Goia M, Recupero D, et al. Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. Front. Oncol. 2013;3:129. doi:10.3389\/fonc.2013.00129.","DOI":"10.3389\/fonc.2013.00129"},{"key":"10.32074\/1591-951X-1565_ref9","doi-asserted-by":"crossref","unstructured":"Zhang H, Katerji H, Turner BM, et al. HER2-Low Breast Cancers. Am. J. Clin. Pathol. 2022;157:328\u2013336. doi:10.1093\/ajcp\/aqab117.","DOI":"10.1093\/ajcp\/aqab117"},{"key":"10.32074\/1591-951X-1565_ref10","doi-asserted-by":"crossref","unstructured":"Zhang H, Peng Y. Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer. Cancers (Basel). 2022;15. doi:10.3390\/cancers15010126.","DOI":"10.3390\/cancers15010126"},{"key":"10.32074\/1591-951X-1565_ref11","doi-asserted-by":"crossref","unstructured":"Sajjadi E, Venetis K, Ivanova M, et al. Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist. (Alhambra, Calif.) 2022;5:882\u2013888. doi:10.20517\/cdr.2022.29.","DOI":"10.20517\/cdr.2022.29"},{"key":"10.32074\/1591-951X-1565_ref12","doi-asserted-by":"crossref","unstructured":"Zhang H, Katerji H, Turner BM, et al. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod. Pathol. 2022;35:1075\u20131082. doi:10.1038\/s41379-022-01019-5.","DOI":"10.1038\/s41379-022-01019-5"},{"key":"10.32074\/1591-951X-1565_ref13","doi-asserted-by":"crossref","unstructured":"Bianchi S, Caini S, Paglierani M, et al. Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO\/CAP Recommendations. Pathol. Oncol. Res. 2015;21:477\u2013485. doi:10.1007\/s12253-014-9852-0.","DOI":"10.1007\/s12253-014-9852-0"},{"key":"10.32074\/1591-951X-1565_ref14","doi-asserted-by":"crossref","unstructured":"Zhang H, Moisini I, Ajabnoor RM, et al. Applying the New Guidelines of HER2 Testing in Breast Cancer. Curr. Oncol. Rep. 2020;22:51. doi:10.1007\/s11912-020-0901-4.","DOI":"10.1007\/s11912-020-0901-4"},{"key":"10.32074\/1591-951X-1565_ref15","doi-asserted-by":"crossref","unstructured":"Jensen SG, Thomas PE, Christensen IJ, et al. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH. APMIS 2020;128:573\u2013582. doi:10.1111\/apm.13076.","DOI":"10.1111\/apm.13076"},{"key":"10.32074\/1591-951X-1565_ref16","doi-asserted-by":"crossref","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159\u2013174.","DOI":"10.2307\/2529310"},{"key":"10.32074\/1591-951X-1565_ref17","doi-asserted-by":"crossref","unstructured":"Bardia A, Hu X, Dent R, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N. Engl. J. Med. 2024;391:2110\u20132122. doi:10.1056\/NEJMoa2407086.","DOI":"10.1056\/NEJMoa2407086"},{"key":"10.32074\/1591-951X-1565_ref18","unstructured":"College of American Pathologists. CAP QCDR Measure Formalin Fixation Time - Breast Cancer Specimens.; 2018."},{"key":"10.32074\/1591-951X-1565_ref19","doi-asserted-by":"crossref","unstructured":"Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013;31:3997\u20134013. doi:10.1200\/JCO.2013.50.9984.","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"10.32074\/1591-951X-1565_ref20","doi-asserted-by":"crossref","unstructured":"Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod. Pathol. 2012;25:1098\u20131105. doi:10.1038\/modpathol.2012.59.","DOI":"10.1038\/modpathol.2012.59"},{"key":"10.32074\/1591-951X-1565_ref21","doi-asserted-by":"crossref","unstructured":"Lucas E, Jabbar SB, Molberg K, et al. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma. Appl. Immunohistochem. Mol. Morphol. AIMM 2019;27:403\u2013409. doi:10.1097\/PAI.0000000000000646.","DOI":"10.1097\/PAI.0000000000000646"},{"key":"10.32074\/1591-951X-1565_ref22","doi-asserted-by":"crossref","unstructured":"Mayr D, Heim S, Werhan C, et al. Comprehensive immunohistochemical analysis of Her-2\/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2\/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Arch. 2009;454:241\u2013248. doi:10.1007\/s00428-009-0728-8.","DOI":"10.1007\/s00428-009-0728-8"},{"key":"10.32074\/1591-951X-1565_ref23","unstructured":"College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast.; 2023."},{"key":"10.32074\/1591-951X-1565_ref24","doi-asserted-by":"crossref","unstructured":"Torlakovic EE, Francis G, Garratt J, et al. Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Appl. Immunohistochem. Mol. Morphol. AIMM 2014;22:241\u2013252. doi:10.1097\/PAI.0000000000000069.","DOI":"10.1097\/PAI.0000000000000069"},{"key":"10.32074\/1591-951X-1565_ref25","doi-asserted-by":"crossref","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J. Oncol. Pract. 2018;14:437\u2013441. doi:10.1200\/JOP.18.00206.","DOI":"10.1200\/JOP.18.00206"},{"key":"10.32074\/1591-951X-1565_ref26","doi-asserted-by":"crossref","unstructured":"Bonizzi G, Zattoni L, Capra M, et al. Standard operating procedures for biobank in oncology. Front. Mol. Biosci. 2022;9:967310. doi:10.3389\/fmolb.2022.967310.","DOI":"10.3389\/fmolb.2022.967310"},{"key":"10.32074\/1591-951X-1565_ref27","doi-asserted-by":"crossref","unstructured":"Evans AJ, Brown RW, Bui MM, et al. Validating Whole Slide Imaging Systems for Diagnostic Purposes in Pathology: Guideline Update From the College of American Pathologists in Collaboration With the American Society for Clinical Pathology and the Association for Pathology Informatics. Arch. Pathol. Lab. Med. 2021. doi:10.5858\/arpa.2020-0723-CP.","DOI":"10.5858\/arpa.2020-0723-CP"},{"key":"10.32074\/1591-951X-1565_ref28","doi-asserted-by":"crossref","unstructured":"Fraggetta F, L\u2019Imperio V, Ameisen D, et al. Best Practice Recommendations for the Implementation of a Digital Pathology Workflow in the Anatomic Pathology Laboratory by the European Society of Digital and Integrative Pathology (ESDIP). Diagnostics (Basel, Switzerland) 2021;11. doi:10.3390\/diagnostics11112167.","DOI":"10.3390\/diagnostics11112167"},{"key":"10.32074\/1591-951X-1565_ref29","doi-asserted-by":"crossref","unstructured":"Marletta S, Caputo A, Guidi G, et al. Digital Pathology Displays Under Pressure: Benchmarking Performance Across Market Grades. J. Imaging Informatics Med. 2025. doi:10.1007\/s10278-025-01452-3.","DOI":"10.1007\/s10278-025-01452-3"},{"key":"10.32074\/1591-951X-1565_ref30","doi-asserted-by":"crossref","unstructured":"Marchi\u00f2 C, Annaratone L, Marques A, et al. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin. Cancer Biol. 2021;72:123\u2013135. doi:10.1016\/j.semcancer.2020.02.016.","DOI":"10.1016\/j.semcancer.2020.02.016"},{"key":"10.32074\/1591-951X-1565_ref31","doi-asserted-by":"crossref","unstructured":"Marletta S, Castellano I, Caumo F et al. Consensus document on preoperative diagnostic procedures in breast lesions. Pathologica. 2025 Jun;117(3):178-198. https:\/\/doi.org\/10.32074\/1591-951X-1113. PMID: 40626666; PMCID: PMC12236140.","DOI":"10.32074\/1591-951X-1113"},{"key":"10.32074\/1591-951X-1565_ref32","doi-asserted-by":"crossref","unstructured":"Geukens T, De Schepper M, Richard F, et al. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. Eur. J. Cancer 2023;188:152\u2013160. doi:10.1016\/j.ejca.2023.04.026.","DOI":"10.1016\/j.ejca.2023.04.026"},{"key":"10.32074\/1591-951X-1565_ref33","doi-asserted-by":"crossref","unstructured":"Marletta S, Giorlandino A, Cavallo E, et al. Discordance of Biomarker Expression Profile between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis in Preoperative Core Needle Biopsy. Diagnostics (Basel, Switzerland) 2024;14. doi:10.3390\/diagnostics14030259.","DOI":"10.3390\/diagnostics14030259"},{"key":"10.32074\/1591-951X-1565_ref34","doi-asserted-by":"crossref","unstructured":"Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 2021;7:137. doi:10.1038\/s41523-021-00343-4.","DOI":"10.1038\/s41523-021-00343-4"},{"key":"10.32074\/1591-951X-1565_ref35","doi-asserted-by":"crossref","unstructured":"Biganzoli L, Cardoso F, Beishon M, et al. The requirements of a specialist breast centre. The Breast 2020;51:65\u201384. doi:https:\/\/doi.org\/10.1016\/j.breast.2020.02.003.","DOI":"10.1016\/j.breast.2020.02.003"},{"key":"10.32074\/1591-951X-1565_ref36","doi-asserted-by":"crossref","unstructured":"van Es SC, van der Vegt B, Bensch F, et al. Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results. Am. J. Surg. Pathol. 2019;43:1355\u20131360. doi:10.1097\/PAS.0000000000001321.","DOI":"10.1097\/PAS.0000000000001321"},{"key":"10.32074\/1591-951X-1565_ref37","doi-asserted-by":"crossref","unstructured":"Zeng J, Piscuoglio S, Aggarwal G, et al. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies. Cancer Cytopathol. 2020;128:133\u2013145. doi:10.1002\/cncy.22226.","DOI":"10.1002\/cncy.22226"},{"key":"10.32074\/1591-951X-1565_ref38","doi-asserted-by":"crossref","unstructured":"Clark BZ, Yoest JM, Onisko A, et al. Effects of Hydrochloric Acid and Formic Acid Decalcification on Breast Tumor Biomarkers and HER2 Fluorescence In Situ Hybridization. Appl. Immunohistochem. Mol. Morphol. AIMM 2019;27:223\u2013230. doi:10.1097\/PAI.0000000000000564.","DOI":"10.1097\/PAI.0000000000000564"},{"key":"10.32074\/1591-951X-1565_ref39","doi-asserted-by":"crossref","unstructured":"Fernandez AI, Liu M, Bellizzi A, et al. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 2022;8:1\u20134. doi:10.1001\/jamaoncol.2021.7239.","DOI":"10.1001\/jamaoncol.2021.7239"},{"key":"10.32074\/1591-951X-1565_ref40","doi-asserted-by":"crossref","unstructured":"Viale G, Basik M, Niikura N, et al. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open 2023;8:101615. doi:10.1016\/j.esmoop.2023.101615.","DOI":"10.1016\/j.esmoop.2023.101615"},{"key":"10.32074\/1591-951X-1565_ref41","doi-asserted-by":"crossref","unstructured":"R\u00fcschoff J, Penner A, Ellis IO, et al. Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer. Arch. Pathol. Lab. Med. 2024. doi:10.5858\/arpa.2024-0052-OA.","DOI":"10.5858\/arpa.2024-0052-OA"},{"key":"10.32074\/1591-951X-1565_ref42","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs A, Klint L, Linderholm B, Parris TZ. Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence. Breast Cancer Res Treat. 2025 Oct;213(3):397-408. https:\/\/doi.org\/10.1007\/s10549-025-07776-6. Epub 2025 Jul 22. PMID: 40694190; PMCID: PMC12396990.","DOI":"10.1007\/s10549-025-07776-6"},{"key":"10.32074\/1591-951X-1565_ref43","doi-asserted-by":"crossref","unstructured":"Wu S, Yue M, Zhang J, et al. The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer. Mod. Pathol. 2023;36:100054. doi:10.1016\/j.modpat.2022.100054.","DOI":"10.1016\/j.modpat.2022.100054"},{"key":"10.32074\/1591-951X-1565_ref44","doi-asserted-by":"crossref","unstructured":"Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 2023;29:2110\u20132120. doi:10.1038\/s41591-023-02478-2.","DOI":"10.1038\/s41591-023-02478-2"},{"key":"10.32074\/1591-951X-1565_ref45","doi-asserted-by":"crossref","unstructured":"Gustavson MD, Haneder S, Spitzmueller A, et al. Abstract PD6-01: Novel approach to HER2 quantification: Digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients. Cancer Res. 2021. Available at: https:\/\/api.semanticscholar.org\/CorpusID:233904204.","DOI":"10.1158\/1538-7445.SABCS20-PD6-01"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:32:42Z","timestamp":1775737962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-1565","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"3"}}